The Searle Company Limited (SEARL) has received approval from the Drug Regulatory Authority of Pakistan (DRAP) to market and sell Denosumab injections, a biosimilar therapy widely used in osteoporosis treatment and oncology care.
In a filing to the Pakistan Stock Exchange (PSX) on Monday, SEARL confirmed the registration of Denosumab in 60mg and 120mg dosages. The company secured rights under a licensing agreement with China’s Mabwell Pharmaceuticals, the original manufacturer, to distribute the biosimilar in Pakistan.
Denosumab, a monoclonal antibody, is prescribed for osteoporosis management (60mg) and as part of oncology treatment (120mg). SEARL said it is now gearing up for the commercial launch of the product, terming it a “significant milestone” in its portfolio expansion.
“This reflects our commitment to strengthening business fundamentals, improving earnings quality, and creating greater value for shareholders,” the company stated.
READ MORE: Punjab Approves Formation of New Anti-Drug Force
SEARL, established in 1965 and a subsidiary of International Brands (Private) Limited, operates in the pharmaceutical, consumer health, and nutritional products sectors.
